Abstract:The Raf Kinase Inhibitor Protein (RKIP) is a unique gene product that directly inhibits the Raf/Mek/Erk and NF-kB pathways in cancer cells and resulting in the inhibition of cell proliferation, viability, EMT, and metastasis. Additionally, RKIP is involved in the regulation of cancer cell resistance to both chemotherapy and immunotherapy. The low expression of RKIP expression in many cancer types is responsible, in part, for the pathogenesis of cancer and its multiple properties. The inhibition of EMT and metastasis by RKIP led to its classification as a tumor suppressor. However, the mechanism by which RKIP mediates its inhibitory effects on EMT and metastases was not clear. We have proposed that one mechanism involves the negative regulation by RKIP of the expression of various gene products that mediate the mesenchymal phenotype as well as the positive regulation of gene products that mediate the epithelial phenotype via signaling cross talks between RKIP and each gene product. We examined several EMT mesenchymal gene products such as Snail, vimentin, N-cadherin, laminin and EPCAM and epithelial gene products such as E-cadherin and laminin. We have found that indeed these negative and positive correlations were detected in the signaling cross-talks. In addition, we have also examined bioinformatic data sets on different human cancers and the findings corroborated, in large part, the findings observed in the signaling cross-talks with few exceptions in some cancer types. The overall findings support the underlying mechanism by which the tumor suppressor RKIP regulates the expression of gene products involved in EMT and metastasis. Hence, the development of agent that can selectively induce RKIP expression in cancers with low expressions should result in the activation of the pleiotropic anti-cancer activities of RKIP and resulting in multiple effects including inhibition of tumor cell proliferation, EMT, metastasis and sensitization of resistant tumor cells to respond to both chemotherapeutics and immunotherapeutics.

Dephosphorylation of the Retinoblastoma protein (Rb) inhibits cancer cell EMT via Zeb

Rho Kinase Phosphorylation Promotes Ezrin-Mediated Metastasis in Hepatocellular Carcinoma

Inhibition of Rb Phosphorylation Leads to Mtorc2-Mediated Activation of Akt

Understanding Retinoblastoma Post-Translational Regulation for the Design of Targeted Cancer Therapies

The ZEB1 Transcription Factor Acts in a Negative Feedback Loop with Mir200 Downstream of Ras and Rb1 to Regulate Bmi1 Expression

RB1 loss induces quiescent state through downregulation of RAS signaling in mammary epithelial cells

Targeting retinoblastoma protein for degradation by proteasomes.

Sequential Inductions of the ZEB1 Transcription Factor Caused by Mutation of Rb and then Ras Proteins Are Required for Tumor Initiation and Progression

PTPRB promotes metastasis of colorectal carcinoma via inducing epithelial-mesenchymal transition

Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression.

Rb Loss Promotes Prostate Cancer Metastasis

PTEN depletion reduces H3K27me3 levels to promote epithelial-to-mesenchymal transition in epithelial colorectal cancer cells

53BP1 suppresses epithelial–mesenchymal transition by downregulating ZEB1 through microRNA‐200b/429 in breast cancer

Differential Impact of RB Status on E2F1 Reprogramming in Human Cancer

Identification of Epigenetically Modified Hub Genes and Altered Pathways Associated With Retinoblastoma

An Rb1-dependent amplification loop between Ets1 and Zeb1 is evident in thymocyte differentiation and invasive lung adenocarcinoma

SUMOylation of Rb Enhances Its Binding with CDK2 and Phosphorylation at Early G1 Phase

Constitutive Expression of Rbap46 Induces Epithelial-Mesenchymal Transition in Mammary Epithelial Cells

Effect of PTPRB on Metastasis of Colorectal Carcinoma and Induction of Epithelial-Mesenchymal Transition.

The Role of RKIP in the Regulation of EMT in the Tumor Microenvironment

Correction To: CDK4/6 Inhibition Blocks Cancer Metastasis Through a USP51-ZEB1-dependent Deubiquitination Mechanism